Such validation studies might include PD cohorts enriched for a specific PD associated genotype (eg. GBA1 mutations) or functional research on patient derived biomaterial by reprogramming of induced pluripotent stem cells (eg. organ-on-a-chip, human intestinal organoids). The gene discussed is GBA1; the disease is Parkinson disease.